Heidelberg Pharma AG
XETRA:HPHA
Heidelberg Pharma AG
Net Income (Common)
Heidelberg Pharma AG
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Heidelberg Pharma AG
XETRA:HPHA
|
Net Income (Common)
-€20.3m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
BioNTech SE
NASDAQ:BNTX
|
Net Income (Common)
€930.3m
|
CAGR 3-Years
296%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
MorphoSys AG
XETRA:MOR
|
Net Income (Common)
-€189.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
Immatics NV
NASDAQ:IMTX
|
Net Income (Common)
-€97m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
Biotest AG
XETRA:BIO
|
Net Income (Common)
€127m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-7%
|
CAGR 10-Years
15%
|
|
Formycon AG
XETRA:FYB
|
Net Income (Common)
€36m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Heidelberg Pharma AG's Net Income (Common)?
Net Income (Common)
-20.3m
EUR
Based on the financial report for Nov 30, 2023, Heidelberg Pharma AG's Net Income (Common) amounts to -20.3m EUR.
What is Heidelberg Pharma AG's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-12%
Over the last year, the Net Income (Common) growth was -3%. The average annual Net Income (Common) growth rates for Heidelberg Pharma AG have been -3% over the past three years , -12% over the past five years .